Download App

Log in to access Online Inquiry
Company Overview More
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
CEO: --
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

ALLO Allogene Therapeutics
7.379+0.299+4.22%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-35.81% 449.05M -44.76% 457.3M -21.57% 809.48M -42.51% 483.49M
-Cash and cash equivalents
-64.32% 84.51M -5.47% 173.31M -21.57% 809.48M 20.16% 190.02M
-Short-term investments
-21.22% 364.54M -55.94% 283.99M -- -- -57.03% 293.46M
Prepaid assets
25.57% 20.69M -18.58% 14.02M -- -- 48.61% 19.37M
Total current assets
-34.4% 469.74M -44.23% 471.32M -- 809.48M -41.12% 502.86M
Non current assets
Net PPE
8.52% 177.26M 13.04% 181.02M -- -- 14.17% 164.65M
-Gross PPE
14.68% 204.31M 18.11% 204.38M -- -- 18.35% 183.77M
-Accumulated depreciation
-82.48% -27.05M -80.98% -23.36M -- -- -72.82% -19.12M
Investments and advances
5.06% 298.3M 78.02% 370.18M -- -- 86.41% 396.13M
Other non current assets
22.96% 19.33M 10.19% 16.11M -- -- 33.15% 15.61M
Total non current assets
6.89% 494.89M 48.24% 567.31M -- 229.15M 56.44% 576.39M
Total assets
-18.19% 964.63M -15.41% 1.04B -15.41% 1.04B -11.72% 1.08B
Liabilities
Current liabilities
Payables
-41.46% 8.71M -1.3% 10.26M -- -- 13.28% 11.5M
-accounts payable
-41.46% 8.71M -1.3% 10.26M -- -- 13.28% 11.5M
Current accrued expenses
-30.13% 27.76M -7.8% 21.37M -- -- 4.12% 41.63M
Current deferred liabilities
69.87% 406K -98.92% 423K -- -- -- 365K
Current liabilities
-32.77% 36.88M -48.92% 48.17M -- -- 6.7% 53.49M
Non current liabilities
Long term debt and capital lease obligation
33.72% 69.04M 37.63% 69.93M -- -- -0.41% 50.64M
-Long term capital lease obligation
33.72% 69.04M 37.63% 69.93M -- -- -0.41% 50.64M
Other non current liabilities
25.04% 3.49M 33.8% 4.13M -- -- 85.28% 5.18M
Total non current liabilities
33.28% 72.53M 37.41% 74.05M -- -- 4.05% 55.81M
Total liabilities
0.13% 109.4M -17.53% 122.23M -17.53% 122.23M 5.33% 109.3M
Shareholders'equity
Share capital
1.42% 143K 1.43% 142K -- -- 1.43% 142K
-common stock
1.42% 143K 1.43% 142K -- -- 1.43% 142K
-Preferred stock
-- 0 -- 0 -- -- -- 0
Retained earnings
-44.72% -983.2M -39.76% -903.35M -- -- -43.39% -828.48M
Paid-in capital
5.63% 1.85B 5.6% 1.82B -- -- 6.09% 1.8B
Gains losses not affecting retained earnings
-9057.43% -9.25M -1057.84% -2.57M -- -- -141.76% -398K
Total stockholders'equity
-20.06% 855.23M -15.12% 916.41M -15.12% 916.41M -13.3% 969.94M
Total equity
-20.06% 855.23M -15.12% 916.41M -15.12% 916.41M -13.3% 969.94M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%